Table 3. FAB/LMB and BFM Staging Schemas for B-cell NHL
| Stratum | Disease Manifestation | |
| ALL = acute lymphoblastic leukemia; BFM = Berlin-Frankfurt-Munster; CNS= central nervous system; FAB = French-American-British; LDH = lactate dehydrogenase; NHL = non-Hodgkin lymphoma. | ||
| FAB/LMB International Study [3-5] | A | Completely resected stage I and abdominal stage II |
| B | Multiple extra-abdominal sites | |
| Nonresected stage I and II, III, IV (marrow <25% blasts, no CNS disease) | ||
| C | Mature B-cell ALL (>25% blasts in marrow) and/or CNS disease | |
| BFM Group [6] | R1 | Completely resected stage I and abdominal stage II |
| R2 | Nonresected stage I/II and stage III with LDH <500 IU/L | |
| R3 | Stage III with LDH 500–999 IU/L | |
| Stage IV, B-ALL (>25% blasts), no CNS disease, and LDH <1,000 IU/L | ||
| R4 | Stage III, IV, B-cell ALL with LDH >1,000 IU/L | |
| Any CNS disease | ||
References
- Patte C, Auperin A, Gerrard M, et al.: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109 (7): 2773-80, 2007. [PUBMED Abstract]
- Gerrard M, Cairo MS, Weston C, et al.: Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 141 (6): 840-7, 2008. [PUBMED Abstract]
- Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 94 (10): 3294-306, 1999. [PUBMED Abstract]
